摘要
我国是全球22个结核病流行严重的国家之一,同时也是全球27个耐多药结核病流行严重的国家之一。耐多药结核病在许多国家已成为主要公共卫生问题,而研发新型抗结核药物是有效遏制结核病流行和提高结核病防治效果的重要环节之一。本文介绍结核病、尤其是耐多药结核病的流行现状以及抗结核药物研发的最新进展。
China is one of the 22 countries with serious tuberculosis epidemic in the whole world and is also one of the 27 countries with the serious multidrug-resistant tuberculosis （MDR-TB）. MDR-TB has become the tough problem of public health in many countries. It is an important link to study and develop the new anti-tubercul0sis drugs to prevent and control tuberculosis and to improve their efficacy. This article introduces the tuberculosis, especially epidemic status of drug-resistant tuberculosis and research progress of anti-tuberculosis drugs.
出处
《上海医药》
CAS
2013年第13期3-7,共5页
Shanghai Medical & Pharmaceutical Journal
关键词
结核病
耐多药结核病
流行病学
抗结核药物
tuberculosis
multidrug-resistant tuberculosis
epidemic
anti-tuberculosis drugs
